Kymera Therapeutics, Inc. · NASDAQ:KYMR
Booth Bruce sold 513,245 Kymera Therapeutics, Inc. shares (Form 4)
Traded Jun 26 to Jun 29, 2026 · Filed Jun 30, 2026
From Jun 26 to Jun 29, 2026, Booth Bruce (Director) sold 513,245 Kymera Therapeutics, Inc. shares at an average US$110.01 for US$56.5M under a trading plan, leaving 466,077 shares. Filed Jun 30, 2026 (Form 4).
- Sold
- 513,245 shares
- Price
- US$110.01 average (US$105.78 to US$118.66)
- Value
- US$56.5M
- Holding after
- 466,077 shares (held indirectly)
- Trading plan
- Yes (Made under a plan set in advance)
- Role
- Director
The filing in full
| Date | Security | Transaction | Shares | Price | Holding after | Ownership |
|---|---|---|---|---|---|---|
| Jun 26, 2026 | Common Stock | Sale | 28,296 | US$107.57 | 2,834,055 | Indirect |
| Jun 26, 2026 | Common Stock | Sale | 231,007 | US$108.14 | 2,603,048 | Indirect |
| Jun 26, 2026 | Common Stock | Sale | 32,624 | US$109.79 | 2,570,424 | Indirect |
| Jun 26, 2026 | Common Stock | Sale | 11,277 | US$110.49 | 2,559,147 | Indirect |
| Jun 26, 2026 | Common Stock | Sale | 10,366 | US$111.51 | 2,548,781 | Indirect |
| Jun 26, 2026 | Common Stock | Sale | 555 | US$112.49 | 2,548,226 | Indirect |
| Jun 26, 2026 | Common Stock | Sale | 14,913 | US$113.97 | 2,533,313 | Indirect |
| Jun 26, 2026 | Common Stock | Sale | 27,951 | US$114.94 | 2,505,362 | Indirect |
| Jun 26, 2026 | Common Stock | Sale | 6,821 | US$115.69 | 2,498,541 | Indirect |
| Jun 26, 2026 | Common Stock | Sale | 12,181 | US$117.09 | 2,486,360 | Indirect |
| Jun 26, 2026 | Common Stock | Sale | 22,046 | US$117.85 | 2,464,314 | Indirect |
| Jun 26, 2026 | Common Stock | Sale | 12,390 | US$118.66 | 2,451,924 | Indirect |
| Jun 26, 2026 | Common Stock | Sale | 3,958 | US$107.57 | 525,760 | Indirect |
| Jun 26, 2026 | Common Stock | Sale | 32,402 | US$108.14 | 493,358 | Indirect |
| Jun 26, 2026 | Common Stock | Sale | 4,562 | US$109.79 | 488,796 | Indirect |
| Jun 26, 2026 | Common Stock | Sale | 1,579 | US$110.49 | 487,217 | Indirect |
| Jun 26, 2026 | Common Stock | Sale | 1,442 | US$111.51 | 485,775 | Indirect |
| Jun 26, 2026 | Common Stock | Sale | 78 | US$112.49 | 485,697 | Indirect |
| Jun 26, 2026 | Common Stock | Sale | 2,083 | US$113.97 | 483,614 | Indirect |
| Jun 26, 2026 | Common Stock | Sale | 3,896 | US$114.94 | 479,718 | Indirect |
| Jun 26, 2026 | Common Stock | Sale | 952 | US$115.69 | 478,766 | Indirect |
| Jun 26, 2026 | Common Stock | Sale | 1,701 | US$117.09 | 477,065 | Indirect |
| Jun 26, 2026 | Common Stock | Sale | 3,069 | US$117.85 | 473,996 | Indirect |
| Jun 26, 2026 | Common Stock | Sale | 1,729 | US$118.66 | 472,267 | Indirect |
| Jun 29, 2026 | Common Stock | Sale | 5,471 | US$105.78 | 2,446,453 | Indirect |
| Jun 29, 2026 | Common Stock | Sale | 14,613 | US$106.63 | 2,431,840 | Indirect |
| Jun 29, 2026 | Common Stock | Sale | 19,093 | US$107.76 | 2,412,747 | Indirect |
| Jun 29, 2026 | Common Stock | Sale | 848 | US$105.78 | 471,419 | Indirect |
| Jun 29, 2026 | Common Stock | Sale | 2,318 | US$106.63 | 469,101 | Indirect |
| Jun 29, 2026 | Common Stock | Sale | 3,024 | US$107.76 | 466,077 | Indirect |
Source
Related
- Kymera Therapeutics, Inc.
- Booth Bruce
- Kymera Therapeutics, Inc. shareholders
- Form 4/A · Booth Bruce · Jul 2, 2026
- Form 4 · Booth Bruce · Jun 30, 2026
- Form 4 · Booth Bruce · Jun 25, 2026
- Form 4 · Booth Bruce · Jun 25, 2026
- Form 4 · Booth Bruce · Jun 22, 2026
- Form 4 · Mainolfi Nello · Oct 1, 2026
- Schedule 13G/A · T. Rowe Price Associates Inc · Sep 8, 2026
- Form 4 · Adams Brian · Sep 4, 2026
- Schedule 13G/A · T. Rowe Price Associates Inc · Aug 14, 2026
- Schedule 13G/A · Atlas Venture Fund X, L.P. · Aug 13, 2026